Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$5.53 USD
-0.12 (-2.12%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.67 +0.14 (2.53%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BOLT 5.53 -0.12(-2.12%)
Will BOLT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BOLT
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates
Other News for BOLT
12 Health Care Stocks Moving In Friday's Pre-Market Session
Bolt Metals Completes Debt Settlement to Preserve Cash
BOLT Trading Temporarily Halted as Company Awaits News | BOLT Stock News
Bolt Biotherapeutics Inc trading halted, news pending
Bolt Biotherapeutics Inc trading halted, news pending